Navigation Links
Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
Date:6/30/2008

F(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of glaucoma. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at http://www.decode.com; on our diagnostics website at http://www.decodediagnostics.com; and, for our pioneering personal genome analysis service, at http://www.decodeme.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk fact
'/>"/>

SOURCE deCODE genetics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
2. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
3. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
4. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
5. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
6. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
7. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
8. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
9. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
10. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
11. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 VWR ... laboratory products, services and solutions, announces the redesign of its ... customers. When visiting the new site, guests ... with bold colors and vivid images.  Each country site now ... an A to Z product menu; and , the ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 /PRNewswire/ ... HOLD -- FN Media Group LLC, PIV757417 The ... Focus on Developing Orphan Drug Products & Treatments ... now OFF HOLD. Distribution time: 3 Aug 2015 ... agreements between biotech companies, military surgical research and ...
(Date:8/3/2015)... 2015  Charleston Laboratories, Inc., an emerging specialty ... development program with a Phase 1 study on ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  This novel ... for migraine headache pain and migraine-induced nausea and ... migraine headaches also suffer from nausea and vomiting," ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... , AUSTIN, Texas, Dec. 9 Ascension ... recent hiring of two veteran executives, L. Robert Johnston, Jr. ... Vice President of Marketing. "These individuals bring a wealth of ... future growth of Ascension," said Guy Mayer, CEO. "As members ...
... Dec. 9 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... to the Company,s Board of Directors. Dr. Sanders brings ... physician and professor of medicine. , "We are ... said Zola P. Horovitz, Ph.D., Chairman of the Board of ...
Cached Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4
(Date:8/3/2015)... ... ... an opinion piece published July 28 by the Washington Post, the conventional wisdom ... may not be accurate. While this system may work for some people, the author notes ... both on the individual and at what point that person is in their weight loss ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today ... B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, ... for the launch of their Readmissions Analytics product was selected as one of ...
(Date:8/3/2015)... ... August 03, 2015 , ... A ... while an overwhelming number of Hispanics believe people can positively affect their diabetes, ... of participants queried said making diet changes was important. Far fewer participants mentioned ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact ... AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation ... an organization whose mission is to develop technology for the sake of humanity ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Pediatric rankings include top 30 hospitals in six specialty fields ... ... 30 U.S.News & World Report, one of the,nation,s leading sources of ... Children,s Hospitals,published online at http://www.usnews.com/pediatrics and in the magazine,s,June 9 ...
... Company to evaluate appeal options, TORONTO, May ... PMD; Amex: PME) today announced it has been ... it will not continue to,support PreMD,s plan for ... it intends to delist the Company,s common stock ...
... cancer were more likely than whites to die in ... among blacks for life-extending treatment even in the face ... by researchers at Dana-Farber Cancer Institute in Boston. ,The ... meeting of the American Society of Clinical Oncology in ...
... finds , , FRIDAY, May 30 (HealthDay News) -- Cirque ... to those of elite athletes in competitive sports, say ... 2006. , Injuries of the knee and ankle were ... all injuries to the upper extremities. Most injuries (45 ...
... GLENWOOD, Ill., May 30 Landauer, Inc. (NYSE:,LDR) announced ... cash dividend of $0.50 per share for the third ... July 3, 2008, to shareholders of record,on June 13, ... provider of analytical services to determine,occupational and environmental radiation ...
... One of the Easiest Paths to Fitness, INDIANAPOLIS, May ... fitness method, think again: taking a stroll is,an easy way ... according to three researchers who presented findings today at the,55th ... A study of 14 morbidly obese patients was designed to ...
Cached Medicine News:Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 2Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Black patients with terminal cancer more likely to choose aggressive care at end of life 2Health News:Injury Patterns Similar for 'Circus' Artists, Elite Athletes 2Health News:Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese 2
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: